Johnson & Johnson announced that nipocalimab, an FcRn blocker, met its primary endpoint in the Phase 2 JASMINE study by significantly reducing systemic lupus erythematosus (SLE) disease activity at 24 weeks and sustained improvements through 52 weeks. The drug demonstrated greater efficacy in autoantibody-positive patients (80% of SLE population) with a favorable safety profile. The Phase 3 GARDENIA study is ongoing, and nipocalimab received Fast Track Designation from the FDA in January 2026.

State Street's XLV healthcare ETF outperforms Invesco's RSPH with a lower expense ratio (0.08% vs 0.4%), higher dividend yield (1.72% vs 0.7%), and better 5-year returns ($1,311 vs $1,134 on $1,000 invested). XLV uses market-cap weighting favoring large pharmaceutical companies, while RSPH employs equal-weighting for broader diversification. XLV also demonstrated greater resilience with a lower maximum drawdown over five years.

The article highlights three Dividend Kings—companies with 50+ consecutive years of dividend increases—that combine strong fundamentals with reliable income growth. Johnson & Johnson (64 years of increases) benefits from its pharmaceutical and MedTech focus post-spinoff. PepsiCo (54 years) offers diversified brand portfolio and pricing power. Becton, Dickinson (53 years) provides defensive, recession-resistant revenue from medical supplies with modest growth potential.

Johnson & Johnson announced Phase 3 PROTEUS study results showing ERLEADA® (apalutamide) combined with hormone therapy before and after prostate cancer surgery significantly reduces metastasis/death risk by 20% and increases pathologic complete response rates 9-fold compared to hormone therapy alone in patients with high-risk localized or locally advanced prostate cancer. The findings were presented at ASCO 2026 and published in The New England Journal of Medicine.

Vanguard research suggests value-oriented stocks may outperform tech stocks over the next 5-10 years. The Vanguard High Dividend Yield ETF (VYM), holding 608 large-cap dividend-paying stocks, has delivered 29.5% returns over the past year with a low 0.04% expense ratio and 2.24% dividend yield. The fund offers exposure to quality blue-chip companies like JPMorgan Chase and Johnson & Johnson, though investors should note its concentration risk with Broadcom representing 8% of assets.

With recession concerns rising due to high energy prices and consumer budget tightening, investors should consider adding resilient stocks from consumer staples and healthcare sectors to their portfolios. Four dividend-paying companies recommended for recession-resistant income are Coca-Cola, Procter & Gamble, Johnson & Johnson, and Medtronic, all of which have strong track records of maintaining dividends through economic downturns.

Walmart's stock dropped over 9% following its Q1 earnings due to cautious guidance and concerns about higher fuel costs, despite meeting expectations. However, the article argues this presents a buying opportunity given Walmart's 53-year dividend increase streak, strong growth in Walmart+, advertising revenue (up 36%), and management's optimism about future business potential.

The Vanguard Health Care ETF (VHT) offers broader healthcare sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.69%), while the SPDR S&P Biotech ETF (XBI) provides targeted biotech exposure with higher volatility but stronger recent 1-year returns (62.20% vs 13.00%). VHT is better suited for income-seeking investors seeking diversified healthcare exposure, while XBI appeals to aggressive investors seeking biotech-specific growth.

IHE (U.S. Pharmaceuticals ETF) significantly outperformed IXJ (Global Healthcare ETF) over the past year, driven largely by GLP-1 drug success, particularly from Eli Lilly. While IHE's concentrated focus on domestic pharma delivered 39.70% returns, IXJ's broader global healthcare approach provided more diversification but only 10% returns. Both funds charge similar fees, making the choice dependent on investor preference for concentration versus diversification.

Johnson & Johnson is highlighted as a superior Dividend King investment compared to peers like Procter & Gamble, offering better dividend growth (5.7% vs 2.4% annualized) and business resilience. Despite trading at a premium valuation, J&J's diversified pharmaceutical and medical device portfolio, patent protections, and essential healthcare products make it well-positioned to weather economic uncertainty.

LEVIN Capital Strategies sold 670,374 shares of O-I Glass (worth $9.23 million) in Q1 2026, reducing its stake to 0.84% of AUM. The stock has declined 33.5% over the past year as the company faces structural headwinds from glass being heavier and more expensive to ship than alternatives like aluminum or plastic, combined with a heavy debt load.

The global facial serum market is projected to grow from US$5.0 billion in 2025 to US$7.2 billion by 2032, with a CAGR of 5.2%. Growth is driven by innovations in formulations, personalization through AI-driven skin analysis, clean beauty trends, and expansion of e-commerce channels. Anti-aging serums are expected to reach US$1.8 billion by 2032, while China is forecasted to grow at 8.1% CAGR.